Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
TECX Quote, Financials, Valuation and Earnings
Last price:
$20.87
Seasonality move
:
-18.81%
Day range:
$20.80 - $21.80
52-week range:
$13.70 - $61.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.38x
Volume:
183.1K
Avg. volume:
346.8K
1-year change:
-59.22%
Market cap:
$390.8M
Revenue:
--
EPS (TTM):
-$3.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
-- | -- | -- | -50.01% | $78.71 |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.15 | -- | -22.97% | $22.00 |
|
CHRS
Coherus Oncology, Inc.
|
$13.4M | -$0.29 | -73.33% | -29.42% | $5.67 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
OCGN
Ocugen, Inc.
|
$440K | -$0.06 | 12.57% | -20.55% | $9.00 |
|
VSTM
Verastem, Inc.
|
$5.8M | -$0.61 | -88.84% | -63.78% | $16.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
$20.88 | $78.71 | $390.8M | -- | $0.00 | 0% | -- |
|
AVXL
Anavex Life Sciences Corp.
|
$3.64 | $22.00 | $325.2M | -- | $0.00 | 0% | -- |
|
CHRS
Coherus Oncology, Inc.
|
$1.33 | $5.67 | $160.8M | 1.06x | $0.00 | 0% | 1.84x |
|
CRMD
CorMedix, Inc.
|
$12.53 | $19.00 | $987.2M | 6.10x | $0.00 | 0% | 4.22x |
|
OCGN
Ocugen, Inc.
|
$1.41 | $9.00 | $440.4M | -- | $0.00 | 0% | 77.39x |
|
VSTM
Verastem, Inc.
|
$8.06 | $16.00 | $607.1M | -- | $0.00 | 0% | 37.66x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
-- | 2.257 | -- | 25.30x |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.800 | -- | 11.47x |
|
CHRS
Coherus Oncology, Inc.
|
38.23% | 0.832 | 28.5% | 0.54x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
OCGN
Ocugen, Inc.
|
90.32% | 2.409 | 6.48% | 1.60x |
|
VSTM
Verastem, Inc.
|
121% | -1.113 | 15.18% | 2.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
-- | -$21.9M | -29.15% | -29.43% | -- | -$14.7M |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$10.8M | -44.87% | -44.87% | -- | -$8.6M |
|
CHRS
Coherus Oncology, Inc.
|
$6.9M | -$42.2M | -115.69% | -- | -364.99% | -$46.3M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
OCGN
Ocugen, Inc.
|
$802K | -$17.6M | -139.38% | -345.08% | -1005.99% | -$13M |
|
VSTM
Verastem, Inc.
|
$9.3M | -$40.7M | -369.69% | -1773.4% | -362.17% | -$44.5M |
Tectonic Therapeutic, Inc. vs. Competitors
-
Which has Higher Returns TECX or AVXL?
Anavex Life Sciences Corp. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of --. Tectonic Therapeutic, Inc.'s return on equity of -29.43% beat Anavex Life Sciences Corp.'s return on equity of -44.87%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.02 $267.5M AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M -
What do Analysts Say About TECX or AVXL?
Tectonic Therapeutic, Inc. has a consensus price target of $78.71, signalling upside risk potential of 276.98%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 504.4%. Given that Anavex Life Sciences Corp. has higher upside potential than Tectonic Therapeutic, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Tectonic Therapeutic, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 AVXLAnavex Life Sciences Corp.2 1 0 -
Is TECX or AVXL More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.566, which suggesting that the stock is 56.648% more volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.531%.
-
Which is a Better Dividend Stock TECX or AVXL?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or AVXL?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Anavex Life Sciences Corp. quarterly revenues of --. Tectonic Therapeutic, Inc.'s net income of -$19M is lower than Anavex Life Sciences Corp.'s net income of -$9.8M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19M AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M
-
Which has Higher Returns TECX or CHRS?
Coherus Oncology, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of -384.73%. Tectonic Therapeutic, Inc.'s return on equity of -29.43% beat Coherus Oncology, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.02 $267.5M CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M -
What do Analysts Say About TECX or CHRS?
Tectonic Therapeutic, Inc. has a consensus price target of $78.71, signalling upside risk potential of 276.98%. On the other hand Coherus Oncology, Inc. has an analysts' consensus of $5.67 which suggests that it could grow by 326.07%. Given that Coherus Oncology, Inc. has higher upside potential than Tectonic Therapeutic, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Tectonic Therapeutic, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 CHRSCoherus Oncology, Inc.3 1 0 -
Is TECX or CHRS More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.566, which suggesting that the stock is 56.648% more volatile than S&P 500. In comparison Coherus Oncology, Inc. has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.926%.
-
Which is a Better Dividend Stock TECX or CHRS?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Coherus Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Coherus Oncology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or CHRS?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Coherus Oncology, Inc. quarterly revenues of $11.6M. Tectonic Therapeutic, Inc.'s net income of -$19M is higher than Coherus Oncology, Inc.'s net income of -$44.5M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Coherus Oncology, Inc.'s PE ratio is 1.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 1.84x for Coherus Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19M CHRSCoherus Oncology, Inc.1.84x 1.06x $11.6M -$44.5M
-
Which has Higher Returns TECX or CRMD?
CorMedix, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of 49.9%. Tectonic Therapeutic, Inc.'s return on equity of -29.43% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.02 $267.5M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About TECX or CRMD?
Tectonic Therapeutic, Inc. has a consensus price target of $78.71, signalling upside risk potential of 276.98%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 51.64%. Given that Tectonic Therapeutic, Inc. has higher upside potential than CorMedix, Inc., analysts believe Tectonic Therapeutic, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 CRMDCorMedix, Inc.4 0 0 -
Is TECX or CRMD More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.566, which suggesting that the stock is 56.648% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock TECX or CRMD?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or CRMD?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Tectonic Therapeutic, Inc.'s net income of -$19M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 6.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 4.22x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19M CRMDCorMedix, Inc.4.22x 6.10x $104.3M $108.6M
-
Which has Higher Returns TECX or OCGN?
Ocugen, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of -1144.46%. Tectonic Therapeutic, Inc.'s return on equity of -29.43% beat Ocugen, Inc.'s return on equity of -345.08%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.02 $267.5M OCGNOcugen, Inc.45.78% -$0.07 $36.5M -
What do Analysts Say About TECX or OCGN?
Tectonic Therapeutic, Inc. has a consensus price target of $78.71, signalling upside risk potential of 276.98%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 538.3%. Given that Ocugen, Inc. has higher upside potential than Tectonic Therapeutic, Inc., analysts believe Ocugen, Inc. is more attractive than Tectonic Therapeutic, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 OCGNOcugen, Inc.3 0 0 -
Is TECX or OCGN More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.566, which suggesting that the stock is 56.648% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.
-
Which is a Better Dividend Stock TECX or OCGN?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or OCGN?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Tectonic Therapeutic, Inc.'s net income of -$19M is higher than Ocugen, Inc.'s net income of -$20.1M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 77.39x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19M OCGNOcugen, Inc.77.39x -- $1.8M -$20.1M
-
Which has Higher Returns TECX or VSTM?
Verastem, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of -876.34%. Tectonic Therapeutic, Inc.'s return on equity of -29.43% beat Verastem, Inc.'s return on equity of -1773.4%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.02 $267.5M VSTMVerastem, Inc.82.57% -$1.35 $74M -
What do Analysts Say About TECX or VSTM?
Tectonic Therapeutic, Inc. has a consensus price target of $78.71, signalling upside risk potential of 276.98%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 98.51%. Given that Tectonic Therapeutic, Inc. has higher upside potential than Verastem, Inc., analysts believe Tectonic Therapeutic, Inc. is more attractive than Verastem, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 VSTMVerastem, Inc.8 0 0 -
Is TECX or VSTM More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.566, which suggesting that the stock is 56.648% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.
-
Which is a Better Dividend Stock TECX or VSTM?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or VSTM?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Tectonic Therapeutic, Inc.'s net income of -$19M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 37.66x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19M VSTMVerastem, Inc.37.66x -- $11.2M -$98.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
